Registrations of Patients with Renal Cell Carcinoma in the Nationwide Danish Renal Cancer Database versus the Danish Cancer Registry: Data Quality, Completeness and Survival (DaRenCa Study-3)

Figures & data

Table 1 Completeness and Positive Predictive Value (PPV) of Registrations in DaRenCaData Compared to Registrations in DCR

	DaRenCaData – DCR Patients in Both Registries		DaRenCaData Only	DCR Only	Total	Completeness	PPV
	DaRenCaData N	DCR N	DaRenCa N	DCR N		% (95% CI)	% (95% CI)
01/08/2010–31/07/2011*	649	665	50	145		82 (79–84)	93 (91–95)
01/08/2011–31/07/2012	694	695	26	129		84 (82–87)	96 (95–98)
01/08/2012–31/07/2013	725	715	38	92		89 (87–91)	95 (93–97)
01/08/2013–31/07/2014	849	856	21	93		90 (88–92)	98 (97–99)
01/08/2014–31/07/2015	865	861	24	57		94 (92–95)	97 (96–98)
01/08/2015–31/12/2015	368	358	17	48		88 (85–92)	96 (94–98)
Total	4150 (85%)		176 (4%)	564 (12%)	4890 (100%)	88 (87–89)	96 (95–97)

Notes: *The time periods correspond to the annual reports of DaRenCaData going from August to July; DCR, Danish Cancer Registry; DaRenCaData, Clinical database of the multidisciplinary renal cancer group; PPV Positive Predictive Value: calculated as patients in the intersection in relation to all patients in DaRenCaData; Completeness: Calculated as patients in the intersection in relation to all patients in DCR.

Figure 1 (A) Relative survival for two nationwide renal cell carcinoma registries. Kaplan-Meier curves showing the outcomes for patients registered in DaRenCaData and Danish Cancer Registry. (B) Relative survival based on registry registration. Kaplan-Meier curves showing survival of patients found in both registries (intersection) with DaRenCaData’s date of diagnosis, or with DCR’s date of diagnosis, registration in DaRenCaData only (DaRenCa set difference) and registration in Danish Cancer Registry only (DCR set difference).

Table 2 Relative Survival Based on Registry Registration for DCR and DaRenCaData Patient Populations (Model 1), and Relative Survival for Patients in the Intersection (with Either DCR or DaRenCaData Date of Diagnosis as Entry Point), or Only Registered in DCR or DaRenCaData (Model 2)

	Relative Survival (95% CI)
	1-Year	3-Year	5-Year
Model 1
DCR patient population	81 (79–82)	69 (67–70)	59 (57–61)
DaRenCaData patient population	85 (84–86)	74 (73–76)	65 (63–67)
Model 2
Intersection with DCR date of diagnosis	86 (85–87)	75 (73–77)	66 (64–68)
Intersection with DaRenCaData date of diagnosis	86 (85–88)	76 (74–77)	67 (65–69)
Patients only registered in DCR	52 (48–56)	29 (25–34)	21 (17–25)
Patients only registered in DaRenCaData	64 (56–70)	47 (39–55)	38 (30–46)

Table 3 Mortality Rate Ratios for DCR and DaRenCa Patient Populations (Model 1), and Mortality Rate Ratios for Patients in the Intersection (with Either DCR or DaRenCa Date of Diagnosis as Entry Point), or Only Registered in DCR or DaRenCaData (Model 2)

	HR (95% CI)
	1-Year	3-Year	5-Year
Model 1
DCR patient population	1	1	1
DaRenCaData patient population	0.79 (0.72–0.88)	0.84 (0.78–0.91)	0.86 (0.80–0.92)
Model 2
Intersection with DCR date of diagnosis	1	1	1
Intersection with DaRenCaData date of diagnosis	0.98 (0.88–1.10)	0.98 (0.91–1.07)	0.99 (0.92–1.06)
Patients only registered in DCR	4.29 (3.72–4.93)	3.58 (3.18–4.03)	3.27 (2.92–3.66)
Patients only registered in DaRenCaData	2.84 (2.20–3.68)	2.23 (1.78–2.78)	2.03 (1.64–2.51)

Table 4 1-Year Mortality Rate Ratios with Time Variations for Patients Registered in Both DCR and DaRenCaData (Model 2)

	Number of Deaths	1-Year Mortality Rate Ratio (95% CI)
Time measured as a categorical variable
Period 1 (August 2010 – July 2011)	124	[Reference category]
Period 2 (August 2011 – July 2012)	127	1.04 (0.89–1.22)
Period 3 (August 2012 – July 2013)	120	0.84 (0.71–0.99)
Period 4 (August 2013 – July 2014)	127	0.82 (0.70–0.96)
Period 5 (August 2014 – July 2015)	133	0.74 (0.63–0.87)
Period 6 (August 2015 – December 2015)	58	0.74 (0.60–0.91)
Time measured as a continuous variable
Years between date of diagnosis and start of observation period (August 1st 2010)	–	0.93 (0.90–0.96)